ASA · est 2011OsloParent · 1 subsidiarywas ULTIMOVACS ASA →2025
Brreg · companies
headcount series appears after two register changes
Roles from Brreg, shown for business contact only. No birth date is shown or exported (purpose limitation, GDPR Art. 6(1)(f)).
Brreg · company_people
5 registered roles
| Daglig leder | Namir Jafar Hassan | 2025-03-06 | |
| Styrets leder | Anders Tuv Multiple boards New CEO Serial CEO | 2026-08-17 | |
| Styremedlem | Charlotte Sofie Bergsagel Berg-Svendsen Multiple boards | 2026-08-17 | |
| Styremedlem | Bent Karsten Jakobsen | 2026-08-17 | |
| Styremedlem | Eva-Lotta Coulter | 2026-08-17 |
NOK, amounts in thousands
filed group accounts (konsernregnskap)
| 2024 | 2025 | ||
|---|---|---|---|
| Revenue | 6 110 | ||
| Operating result | −243 393 | −278 623 | |
| Result before tax | −232 412 | −276 500 | |
| Net result | −232 412 | −276 500 | |
| Total assets | 113 529 | 308 070 | |
| Equity | 81 006 | 300 420 |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue | 6 110 | ||||||
| Operating result | −243 393 | −278 623 | |||||
| Result before tax | −232 412 | −276 500 | |||||
| Net result | −232 412 | −276 500 | |||||
| Total assets | 113 529 | 308 070 | |||||
| Equity | 81 006 | 300 420 |
| 2024 | 2025 | ||
|---|---|---|---|
| Revenue | 53 | ||
| Operating result | −109 572 | −143 834 | |
| Result before tax | −105 163 | −140 711 | |
| Net result | −105 163 | −140 711 | |
| Total assets | 50 425 | 103 504 | |
| Equity | 36 040 | 85 857 |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| Revenue | 53 | ||||||
| Operating result | −109 572 | −143 834 | |||||
| Result before tax | −105 163 | −140 711 | |||||
| Net result | −105 163 | −140 711 | |||||
| Total assets | 50 425 | 103 504 | |||||
| Equity | 36 040 | 85 857 |
Regnskapsregisteret · company_revenue · FY2025 (company)
| 2024 | 2025 | ||
|---|---|---|---|
| GJELSTEN HOLDING AS | 19 | 5 | — |
| GEVERAN TRADING COMPANY LTD | — | 10 | — |
| INVEN2 AS | 4 | 8 | — |
| CANICA AS | — | — | — |
| RADFORSK INVESTERINGSSTIFTELSE | 4 | 8 | — |
| BIRK VENTURE AS | — | 6 | — |
| UBS SWITZERLAND AG | 0 | 6 | — |
| WATRIUM AS | — | — | — |
| MERRILL LYNCH, PIERCE, FENNER & SM | — | 5 | — |
| FOLKETRYGDFONDET | — | — | — |
| + 960 smaller holders |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|
| GJELSTEN HOLDING AS | 19 | 19 | 19 | 19 | 19 | 5 | — |
| GEVERAN TRADING COMPANY LTD | — | — | — | — | — | 10 | — |
| INVEN2 AS | 6 | 5 | 5 | 4 | 4 | 8 | — |
| CANICA AS | 8 | 8 | 8 | 8 | — | — | — |
| RADFORSK INVESTERINGSSTIFTELSE | 5 | 4 | 4 | 4 | 4 | 8 | — |
| BIRK VENTURE AS | — | — | — | — | — | 6 | — |
| UBS SWITZERLAND AG | 0 | 0 | 0 | 0 | 0 | 6 | — |
| WATRIUM AS | 5 | 5 | 5 | 5 | — | — | — |
| MERRILL LYNCH, PIERCE, FENNER & SM | — | — | — | — | — | 5 | — |
| FOLKETRYGDFONDET | 4 | 4 | 4 | 1 | — | — | — |
| + 960 smaller holders |
Aksjonærregisteret · company_ownership · 2025 · both directions
register ledger · owners
| 2025-12-31 | own+ | GEVERAN TRADING COMPANY LTD acquired 9.5 pct | |
| 2025-12-31 | own+ | UBS SWITZERLAND AG acquired 5.6 pct | |
| 2025-12-31 | own+ | BIRK VENTURE AS acquired 5.7 pct | |
| 2024-12-31 | own− | CANICA AS exited (held 7.9 pct) | |
| 2024-12-31 | own− | WATRIUM AS exited (held 5.2 pct) |
| 2024 | 2025 | 2026 | |
|---|---|---|---|
| auditor ERNST & YOUNG AS 2015-11-20 | ● | ● | ● |
| accountant AMESTO ACCOUNTHOUSE AS 2018-10-01 | ● | ● | ● |
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|
| auditor ERNST & YOUNG AS 2015-11-20 | ● | ● | ● | ● | ● | ● | ● |
| accountant AMESTO ACCOUNTHOUSE AS 2018-10-01 | ● | ● | ● | ● | ● | ● | ● |
Brreg · company_org_roles
No recorded tender wins.
Relevant open tenders — matched · NACE 72.100 ↔ CPVsubscribers sharpen matches with per-company keywords
open-tender matching (NACE ↔ CPV) awaits Intelligo's open-tenders view
Doffin/TED · company_tender_wins · 2026-08-19
No job ads on record in the last 12 months.
NAV Arbeidsplassen · company_job_ad_months
| Zelluna Immunotherapy AS | 100% | Research and experimental development on natural sciences and engineering | kr 0 |
Aksjonærregisteret · company_ownership · 2025 · both directions
FY202528 full-time equivalentssigned: Anders Tuv, Charlotte Berg-Svendsen, Eva-Lotta Allan, Bent Jakobsen, Hans Ivar Robinson, Namir Hassan
Regnskapsregisteret (årsberetning) · company_annual_reports
17 notes from the report
| Going concern | The filing form states there is no uncertainty about going concern. | “Er det usikkerhet om fortsatt drift?: Nei” |
| Going concern | The board states the current cash position is expected to fund planned operations into the first quarter of 2027. | “support planned operations into the first quarter of 2027.” |
| Dividend | No dividend has historically been distributed and none is expected in the near future. | “The Company has historically not distributed dividends and is not” |
| Dividend | The parent company's loss of MNOK 276.5 is transferred to share premium. | “Zelluna ASA is transferred to Share Premium.” |
| Staff numbers | The notes state man-years for the year (8.50 for the parent, 28.10 for the group). | “Antall arsverk i regnskapsaret” |
| Staff numbers | The group had 24 employees at 31 December 2025 (24 FTEs). | “As per 31 December 2025,the Group had 24 employees, of whom” |
| Related party | Notes disclose no loans or security provided to members of the board or other governing bodies (NOK 0). | “Lan og sikkerhetsstillelse til medlemmer” |
| Share capital | The AGM authorised a share capital increase of up to 20%, corresponding to up to NOK 4,045,413. | “Company's share capital, corresponding to up to NOK 4,045,413” |
| Ownership | Zelluna ASA is a Norwegian public limited company listed on Euronext Oslo Børs. | “Zelluna ASA is a Norwegian public limited liability company (ASA)” |
| Sale process | Ultimovacs ASA completed a business combination with Zelluna on 3 March 2025, accounted for as a reverse acquisition with Zelluna Immunotherapy AS as accounting acquirer. | “On 3 March 2025,Ultimovacs ASA completed a business combina-” |
| Impairment | Group impairment of goodwill and intangible assets of MNOK 5.6 in 2025 (MNOK 2.3 IP licence, MNOK 3.2 goodwill). | “Impairment of goodwill and intangible assets amounted to MNOK” |
| Post balance sheet event | The board reports no significant events after the balance sheet date beyond those described under subsequent events. | “There have been no significant subsequent events after the bal-” |
| Remuneration | Management had no bonus arrangements or separate cash incentive schemes in 2025; only a share option scheme approved by the general meeting. | “For 2025,the Management Team did not have bonus arrange-” |
| Loan or financing | Two private placements were completed in 2025 with deviation from shareholders' pre-emption rights. | “In 2025,the Company completed two private placements where” |
| Restructuring | Following negative phase II readouts, no further development of the UV1 cancer vaccine is planned and the programme is being concluded. | “programme is being concluded.” |
| Subsidiary | The parent balance sheet carries investment in subsidiary of NOK 294 140 000 at 31.12.2025. | “Investering i datterselskap” |
| Other | DNB Bank ASA and Advokatfirmaet Schjødt AS were among the main suppliers/advisers due to the business combination and capital raises in 2025. | “Business Combination and capital raises in 2025, DNB Bank” |
registered 2011-03-29post@zelluna.no
Brreg · companies
register ledger · 24 events
| 2026-08-11 | reg | capital_change: share_capital | 29413759 -> 29860511 |
| 2026-08-11 | reg | capital_change: number_of_shares | 29413759 -> 29860511 |
| 2025-12-31 | report | Going concern | The filing form states there is no uncertainty about going concern. — Er det usikkerhet om fortsatt drift?: Nei |
| 2025-12-31 | report | Going concern | The board states the current cash position is expected to fund planned operations into the first quarter of 2027. — support planned opera... |
| 2025-12-31 | report | Dividend | No dividend has historically been distributed and none is expected in the near future. — The Company has historically not distributed div... |
| 2025-12-31 | report | Dividend | The parent company's loss of MNOK 276.5 is transferred to share premium. — Zelluna ASA is transferred to Share Premium. |
| 2025-12-31 | report | Staff numbers | The notes state man-years for the year (8.50 for the parent, 28.10 for the group). — Antall arsverk i regnskapsaret |
| 2025-12-31 | report | Staff numbers | The group had 24 employees at 31 December 2025 (24 FTEs). — As per 31 December 2025,the Group had 24 employees, of whom |
| 2025-12-31 | report | Related party | Notes disclose no loans or security provided to members of the board or other governing bodies (NOK 0). — Lan og sikkerhetsstillelse til ... |
| 2025-12-31 | report | Share capital | The AGM authorised a share capital increase of up to 20%, corresponding to up to NOK 4,045,413. — Company's share capital, corresponding ... |
| 2025-12-31 | report | Ownership | Zelluna ASA is a Norwegian public limited company listed on Euronext Oslo Børs. — Zelluna ASA is a Norwegian public limited liability com... |
| 2025-12-31 | report | Sale process | Ultimovacs ASA completed a business combination with Zelluna on 3 March 2025, accounted for as a reverse acquisition with Zelluna Immunot... |
| 2025-12-31 | report | Impairment | Group impairment of goodwill and intangible assets of MNOK 5.6 in 2025 (MNOK 2.3 IP licence, MNOK 3.2 goodwill). — Impairment of goodwill... |
| 2025-12-31 | report | Post balance sheet event | The board reports no significant events after the balance sheet date beyond those described under subsequent events. — There have been no... |
| 2025-12-31 | report | Remuneration | Management had no bonus arrangements or separate cash incentive schemes in 2025; only a share option scheme approved by the general meeti... |
| 2025-12-31 | report | Loan or financing | Two private placements were completed in 2025 with deviation from shareholders' pre-emption rights. — In 2025,the Company completed two p... |
| 2025-12-31 | report | Restructuring | Following negative phase II readouts, no further development of the UV1 cancer vaccine is planned and the programme is being concluded. —... |
| 2025-12-31 | report | Subsidiary | The parent balance sheet carries investment in subsidiary of NOK 294 140 000 at 31.12.2025. — Investering i datterselskap |
| 2025-12-31 | report | Other | DNB Bank ASA and Advokatfirmaet Schjødt AS were among the main suppliers/advisers due to the business combination and capital raises in 2... |
| 2025-12-31 | own+ | GEVERAN TRADING COMPANY LTD acquired 9.5 pct | |
| 2025-12-31 | own+ | UBS SWITZERLAND AG acquired 5.6 pct | |
| 2025-12-31 | own+ | BIRK VENTURE AS acquired 5.7 pct | |
| 2024-12-31 | own− | CANICA AS exited (held 7.9 pct) | |
| 2024-12-31 | own− | WATRIUM AS exited (held 5.2 pct) |
Skiwo · company_events